# Amprion

> Amprion is a precision-diagnostics company using Seed Amplification Assay (SAA) technology to detect misfolded proteins - alpha-synuclein, amyloid-beta and tau - in cerebrospinal fluid, giving physicians and drug developers a biological readout of neurodegenerative disease years before symptoms fully emerge. Its flagship SAAmplify-aSYN test (formerly SYNTap) is the first commercially available validated alpha-synuclein SAA, carries an FDA Breakthrough Device Designation, and aims to replace symptom-based guesswork for Parkinson's, Lewy body dementia, Alzheimer's and multiple system atrophy with autopsy-grade certainty.

- **Founded:** 2014
- **Headquarters:** San Francisco, California, United States
- **Founders:** Russell Lebovitz (CEO & Co-Founder), Claudio Soto (Chief Scientific Officer & Co-Founder)
- **Team size:** ~37 employees
- **Products:** SAAmplify-aSYN (formerly SYNTap Biomarker Test), Next-generation SAAmplify biomarker panels, Biopharma services
- **Notable:** FDA Breakthrough Device Designation (2019) for detecting misfolded alpha-synuclein, First commercially available validated alpha-synuclein seed amplification test, Alpha-synuclein SAA used in the landmark Lancet Neurology PPMI study of 1,123 participants (2023)

## Products & services

- **SAAmplify-aSYN (formerly SYNTap Biomarker Test)** — First-in-class qualitative laboratory developed test that detects misfolded alpha-synuclein in cerebrospinal fluid to aid diagnosis of synucleinopathies including Parkinson's disease, Lewy body dementia and Alzheimer's with Lewy body co-pathology. Reported ~96% sensitivity and ~92% specificity, validated across 20,000+ samples and 400+ autopsy confirmations.
- **Next-generation SAAmplify biomarker panels** — CSF panels combining alpha-synuclein SAA with total tau, pTau-181, amyloid-beta 1-42/1-40 and NfL for comprehensive assessment of Parkinson's, Lewy body dementia and Alzheimer's, premiered at AAIC 2024.
- **Biopharma services** — CLIA/CAP lab assays, biomarker tracking, patient stratification, mechanism-of-action and preclinical R&D services that help drug developers enroll pathology-confirmed patients and de-risk clinical trials.

## Achievements

- FDA Breakthrough Device Designation (2019) for detecting misfolded alpha-synuclein
- First commercially available validated alpha-synuclein seed amplification test
- Alpha-synuclein SAA used in the landmark Lancet Neurology PPMI study of 1,123 participants (2023)
- European and UK patents granted for the SAA/PMCA/RT-QuiC platform (2023)
- Co-founder Claudio Soto awarded the Robert A. Pritzker Prize (2024)
- Mayo Clinic Laboratories nationwide distribution agreement (2025)

## Latest updates

- **2026-07** — Announced growth-debt financing from Decathlon Capital Partners and a multimodal-assessment collaboration with Modality.AI.
- **2025-03** — Partnered with Mayo Clinic Laboratories to expand nationwide access to the SAAmplify-aSYN test.
- **2024-10** — Closed an initial $6M of a planned $15M Series B led by Formation Venture Engineering with Eli Lilly participating.
- **2024-07** — Premiered next-generation SAAmplify biomarker panels at AAIC 2024; co-founder Claudio Soto won the Robert A. Pritzker Prize.

## Links

- Website: https://www.ampriondx.com
- LinkedIn: https://www.linkedin.com/company/amprion
- Twitter/X: https://x.com/AmprionME
- YouTube: https://www.youtube.com/watch?v=tqB0fAvyYLM
- Instagram: https://www.instagram.com/amprion/

---

Profile page: https://yespress.io/amprion
Published by YesPress — https://yespress.io
Last updated: 2026-07-13